



CGA M-2—2013
GENERAL GUIDE FOR THE
MANUFACTURE OF
MEDICAL GASES
CLASSIFIED AS DRUGS

SECOND EDITION

PLEASE NOTE:

The information contained in this document was obtained from sources believed to be reliable and is based on technical information and experience currently available from members of the Compressed Gas Association, Inc. and others. However, the Association or its members, jointly or severally, make no guarantee of the results and assume no liability or responsibility in connection with the information or suggestions herein contained. Moreover, it should not be assumed that every acceptable commodity grade, test or safety procedure or method, precaution, equipment or device is contained within, or that abnormal or unusual circumstances may not warrant or suggest further requirements or additional procedure.

This document is subject to periodic review, and users are cautioned to obtain the latest edition. The Association invites comments and suggestions for consideration. In connection with such review, any such comments or suggestions will be fully reviewed by the Association after giving the party, upon request, a reasonable opportunity to be heard. Proposed changes may be submitted via the Internet at our website, www.cganet.com.

This document should not be confused with federal, state, provincial, or municipal specifications or regulations; insurance requirements; or national safety codes. While the Association recommends reference to or use of this document by government agencies and others, this document is purely voluntary and not binding unless adopted by reference in regulations.

A listing of all publications, audiovisual programs, safety and technical bulletins, and safety posters is available via the Internet at our website at www.cganet.com. For more information contact CGA at Phone: 703-788-2700, ext. 799. E-mail: customerservice@cganet.com.

Work Item 09-037
Medical Gases and Equipment Committee

NOTE—Technical changes from the previous edition are underlined.

NOTE—Appendix A (Informative) is for information only.

SECOND EDITION: 2013
FIRST EDITION: 2006

© 2013 The Compressed Gas Association, Inc. All rights reserved.

All materials contained in this work are protected by United States and international copyright laws. No part of this work may be reproduced or transmitted in any form or by any means, electronic or mechanical including photocopying, recording, or any information storage and retrieval system without permission in writing from The Compressed Gas Association, Inc. All requests for permission to reproduce material from this work should be directed to The Compressed Gas Association, Inc., 8484 Westpark Drive, Suite 220, McLean, VA 22102. You may not alter or remove any trademark, copyright or other notice from this work.

Contents	Page
1 Introduction.....	1
2 Scope	1
3 Definitions.....	1
4 Health and safety considerations	6
5 Key laws, regulations, and guidelines	6
5.1 Federal	6
5.2 State	8
6 Standard operating procedures.....	8
7 Organization and Personnel (21 CFR 211 Subpart B)	8
7.1 Quality control unit (21 CFR 211.22)	8
7.2 Personnel qualifications (21 CFR 211.25).....	8
7.3 Personnel responsibilities (21 CFR 211.28).....	9
7.4 Consultants (21 CFR 211.34).....	10
8 Buildings and Facilities (21 CFR 211 Subpart C).....	10
8.1 General.....	10
8.2 Design and construction features (21 CFR 211.42)	10
8.3 Lighting (21 CFR 211.44)	10
8.4 Building maintenance (21 CFR 211.58)	11
8.5 Security.....	11
9 Equipment (21 CFR 211 Subpart D)	11
9.1 Equipment design, size, location and construction (21 CFR 211.63 and 211.65).....	11
9.2 CMG filling systems.....	11
9.3 Product storage	12
9.4 Product filling equipment	12
9.5 Manifold control systems	14
9.6 Equipment cleaning and maintenance (21 CFR 211.67).....	15
9.7 Automatic, mechanical, and electronic equipment (21 CFR 211.68)	16
9.8 Filters (21 CFR 211.72).....	16
10 Control of Components (21 CFR 211 Subpart E).....	16
10.1 General requirements (21 CFR 211.80).....	16
10.2 Receipt and storage of untested components and Testing and approval or rejection of components (21 CFR 211.82 and 211.84)	17
10.3 Certificate of analysis	18
10.4 Retesting of approved components (21 CFR 211.87).....	18
10.5 Rejected components (21 CFR 211.89).....	18
11 Control of Containers and Closures (21 CFR Part 211 Subpart E).....	19
11.1 General requirements (21 CFR 211.80).....	19
11.2 Receipt and storage of untested components, drug product containers, and closures, Testing and approval or rejection of and retesting of drug product containers and closures, and Approved drug product containers and closures (21 CFR 211.82, 211.84, and 211.87)	19
11.3 High pressure cylinders.....	19
11.4 Cryogenic vessels	20
11.5 Vehicle-mounted vessels.....	20
11.6 Portable liquid cryogenic containers.....	20
11.7 Cryogenic home vessels	21
11.8 Dewars (unpressurized)	21
11.9 Rejected drug product containers and closures (21 CFR 211.89)	21

12	Production and Process Controls (21 CFR Part 211 Subpart F)	21
12.1	General information	21
12.2	Written procedures; deviations (21 CFR 211.100)	21
12.3	Charge-in of components (21 CFR 211.101)	22
12.4	Calculation of yield (21 CFR 211.103)	22
12.5	Equipment identification (21 CFR 211.105)	22
12.6	Sampling and testing in-process materials and drug products (21 CFR 211.110)	22
12.7	Time limitations on production, Control of microbiological contamination, and Reprocessing (21 CFR 211.111, 211.113, and 211.115)	23
12.8	Production and process controls	23
13	Packaging and Label Controls (21 CFR Part 211 Subpart G)	23
13.1	General	23
13.2	Labeling requirements	23
13.3	Materials examination and usage control (21 CFR 211.122)	24
13.4	Labeling issuance (21 CFR 211.125)	24
13.5	Labeling operations (21 CFR 211.130)	24
13.6	Drug product inspection (21 CFR 211.134)	24
13.7	Expiration dating (21 CFR 211.137)	25
14	Holding and distribution of finished product (21 CFR Part 211 Subpart H)	25
14.1	Warehousing procedures (21 CFR 211.142)	25
14.2	Distribution procedures (21 CFR 211.150)	25
15	Laboratory Controls (21 CFR Part 211 Subpart I)	26
15.1	General requirements (21 CFR 211.160)	26
15.2	Specifications	26
15.3	Sampling plans	26
15.4	Testing	26
15.5	Calibration of testing equipment	27
15.6	Calibration gas standards	28
15.7	Testing and release for distribution (21 CFR 211.165)	28
16	Records and Reports (21 CFR Part 211 Subpart J)	29
16.1	General requirements (21 CFR 211.180)	29
16.2	Record retention	30
16.3	Record availability	30
16.4	Annual drug product review	30
16.5	Management notification	30
16.6	Equipment cleaning and use log (21 CFR 211.182)	30
16.8	Master production and control records (21 CFR 211.186)	31
16.9	Batch production and control records (21 CFR 211.188)	31
16.10	Production record review (21 CFR 211.192)	32
16.11	Out of specification results	32
16.12	Laboratory records (21 CFR 211.194)	32
16.13	Distribution records (21 CFR 211.196)	33
16.14	Complaint files/procedures (21 CFR 211.198)	33
17	Returned and Salvaged Drug Products (21 CFR Part 211 Subpart K)	33
17.1	Returned drug products (21 CFR 211.204)	33
17.2	Drug product salvaging (21 CFR 211.208)	34
18	References	34
19	Additional references	35
Appendix		
	Appendix A—Typical high pressure oxygen fill record (Informative)	37

1 Introduction

This publication describes the minimum requirements for manufacturing compressed medical gases (CMG) classified as drugs and is intended to aid the manufacturer in complying with the applicable regulations of the U.S. Food and Drug Administration (FDA) and various state agencies, e.g., departments of health and boards of pharmacy. For specific information on federal regulations, see Title 21 of the U.S. *Code of Federal Regulations* (21 CFR) [1].¹

This publication describes the information that shall be addressed in a firm's standard operating procedures (SOP) in order to be in compliance with current regulations. This publication also includes information that should be contained in a firm's SOP. It may not contain the information necessary to comply with all federal and state regulations, so it should be used in conjunction with other compliance publications and guidelines. It is the responsibility of the CMG manufacturer to ensure that their SOP comply with all applicable federal and state regulations.

2 Scope

This publication applies to firms that engage in the filling, repackaging, transfilling, mixing, and/or re-labeling of CMG classified as drugs by the FDA and applicable state agencies. Although it is primarily intended for firms engaged in the CMG manufacturing processes, portions may apply to firms that only distribute CMG classified as drugs.

This publication does not apply to:

- bulk air separation manufacturing and distribution facilities that produce United States Pharmacopoeia/National Formulary (USP/NF) products;
- bulk carbon dioxide USP manufacturing and distribution facilities;
- bulk helium USP manufacturing and distribution facilities;
- bulk nitrous oxide USP manufacturing and distribution facilities;
- drugs that are defined as Investigational New Drug Applications, e.g., a gas or gas mixture that has never been previously used as a drug, New Drug Applications, or Amended New Drug Applications by the *Federal Food, Drug, and Cosmetic Act* (the Act) [2];
- medical gases classified by FDA as medical devices as defined by the Act [2];
- gases labeled for industrial use and recreational applications, e.g., diving gases, self-contained breathing apparatus, aviator's breathing oxygen; or
- refrigerated liquid oxygen USP that is filled at a patient's residence or is filled, repackaged, transfilled, and/or relabeled by home respiratory care companies.

3 Definitions

For the purpose of this publication, the following definitions apply.

3.1 Adulterated

Drug product that does not meet all required or claimed standards of purity, strength, identity, or quality, or that contains a foreign substance that may be injurious to health.

NOTE—A drug product not manufactured in accordance with current good manufacturing practice (CGMP) may also be considered adulterated. See Section 501 of the Act [2].

3.2 Air liquefaction

Process by which air is separated into its component parts by cryogenic distillation.

¹ References are shown by bracketed numbers and are listed in order of appearance in the reference section.